Almirall incorporates Gerhard Mayr to the Board of Directors
- Gerhard Mayr joins the Board of Directors, which will now be made up of 10 members, as an independent board member
- Mayr is an Austrian chemical engineer with extensive international experience in the healthcare sector
Barcelona, 22 October 2012.- The Almirall Extraordinary Shareholders’ Meeting on Friday 19thOctober approved the appointment of Gerhard Mayr as new independent member of the board, by which it will now comprise 10 members.
Mayr has successfully managed several business models in the pharmaceutical and healthcare sector. He is currently President of the Board of Directors of UCB and a member of the Board of Lonza.
Gerhard Mayr is Austrian and studied chemical engineering. His successful career spans over 40 years in various leading companies in the pharmaceutical sector. His strategic vision, outstanding innovative capacity, leadership in stock market environments and extensive international experience advocate his appointment as board member.
About Almirall Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing. Almirall focuses its research resources on respiratory, gastrointestinal, dermatology and pain. Almirall’s medicines are currently present in over 70 countries while it has direct presence in Europe, México and Canada through 13 affiliates.
For further information please visit the website at: www.almirall.com
More information: Investor Relations enquiries: Ketchum Pleon Almirall Sonia San Segundo Jordi Molina sonia.sansegundo@ketchum.com jordi.molina@almirall.com Tel.: 00 34 91 788 32 00 Tel.: 00 34 93 291 30 87
Press release